JP2013100286A5 - - Google Patents

Download PDF

Info

Publication number
JP2013100286A5
JP2013100286A5 JP2012253108A JP2012253108A JP2013100286A5 JP 2013100286 A5 JP2013100286 A5 JP 2013100286A5 JP 2012253108 A JP2012253108 A JP 2012253108A JP 2012253108 A JP2012253108 A JP 2012253108A JP 2013100286 A5 JP2013100286 A5 JP 2013100286A5
Authority
JP
Japan
Prior art keywords
prdm14
anticancer drug
inhibits
antibody
shrna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012253108A
Other languages
English (en)
Japanese (ja)
Other versions
JP5395246B2 (ja
JP2013100286A (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2012253108A priority Critical patent/JP5395246B2/ja
Priority claimed from JP2012253108A external-priority patent/JP5395246B2/ja
Publication of JP2013100286A publication Critical patent/JP2013100286A/ja
Publication of JP2013100286A5 publication Critical patent/JP2013100286A5/ja
Application granted granted Critical
Publication of JP5395246B2 publication Critical patent/JP5395246B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012253108A 2006-09-27 2012-11-19 乳癌および卵巣癌の治療薬、検出方法ならびに検出用キット Active JP5395246B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2012253108A JP5395246B2 (ja) 2006-09-27 2012-11-19 乳癌および卵巣癌の治療薬、検出方法ならびに検出用キット

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2006263232 2006-09-27
JP2006263232 2006-09-27
JP2012253108A JP5395246B2 (ja) 2006-09-27 2012-11-19 乳癌および卵巣癌の治療薬、検出方法ならびに検出用キット

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008536470A Division JP5219818B2 (ja) 2006-09-27 2007-09-27 乳癌および卵巣癌の治療薬、検出方法ならびに検出用キット

Publications (3)

Publication Number Publication Date
JP2013100286A JP2013100286A (ja) 2013-05-23
JP2013100286A5 true JP2013100286A5 (enExample) 2013-07-04
JP5395246B2 JP5395246B2 (ja) 2014-01-22

Family

ID=39230258

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2008536470A Active JP5219818B2 (ja) 2006-09-27 2007-09-27 乳癌および卵巣癌の治療薬、検出方法ならびに検出用キット
JP2012253108A Active JP5395246B2 (ja) 2006-09-27 2012-11-19 乳癌および卵巣癌の治療薬、検出方法ならびに検出用キット

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008536470A Active JP5219818B2 (ja) 2006-09-27 2007-09-27 乳癌および卵巣癌の治療薬、検出方法ならびに検出用キット

Country Status (2)

Country Link
JP (2) JP5219818B2 (enExample)
WO (1) WO2008038832A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6683986B2 (ja) * 2013-07-10 2020-04-22 国立大学法人 東京大学 がん幹細胞分子マーカー
SG10201607303YA (en) * 2016-09-01 2018-04-27 Agency Science Tech & Res Antisense oligonucleotides to induce exon skipping
JP6898617B2 (ja) * 2017-09-26 2021-07-07 国立大学法人 東京大学 Ｐｒｄｍ１４発現を確認する方法
EP3996684A4 (en) * 2019-07-09 2024-06-19 Ariz Precision Medicine, Inc. CANCER TREATMENT USING TARGETED PHARMACEUTICAL SIRNA FORMULATIONS TO DECREASE THE EXPRESSION OF THE PRDM14 PROTEIN
CN116113421A (zh) 2020-05-14 2023-05-12 阿莱兹精准医疗公司 使用siRNA调节PRDM2/RIZ蛋白表达的癌症治疗

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6955905B2 (en) * 2001-07-18 2005-10-18 The Burnham Institute PR/SET-domain containing nucleic acids, polypeptides, antibodies and methods of use

Similar Documents

Publication Publication Date Title
JP2015503422A5 (enExample)
EA201890272A1 (ru) Axl-специфические конъюгаты антитело-лекарственное средство для лечения рака
SG11201405159WA (en) Functional pla-peg copolymers, the nanoparticles thereof, their preparation and use for targeted drug delivery and imaging
WO2014191359A9 (en) Aptamers and use of the aptamers in the diagnosis and treatment of cancer
FR2949470B1 (fr) Derives anticancereux, leur preparation et leur application therapeutique
HUE061596T2 (hu) Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
HRP20220897T8 (hr) Kombinirana terapija koja uključuje antitijela protiv klaudina 18.2 za liječenje raka
BR112014024848A2 (pt) terapia de combinação com um agente antihialuronano e um taxano direcionamento ao tumor
IL238638A0 (en) Dosage and Administration of Oligonucleotide Cancer Therapies
WO2013130703A3 (en) Inhibitors of hepatitis b virus covalently closed circular dna formation and their method of use
JP2015516989A5 (enExample)
HUE054621T2 (hu) Gyógyászáti készítmény, kezelési eljárások és alkalmazásaik
SI3049117T1 (sl) Dostava zdravil, posredovana z ultrazvokom
HK1221424A1 (zh) 治疗癌症的药物组合
MX2015010083A (es) Nanoparticulas biodegradables y clinicamente compatibles como portadores para administracion de farmacos.
EP4458859A3 (en) Conjugate of anti-cdh3 (p-cadherin) antibody and drug
SG11201602429QA (en) Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
JP2013100286A5 (enExample)
BR112014027905A2 (pt) anticorpo, célula, ácido nucleico, métodos de identificação de um primeiro anticorpo, de inibição do crescimento de uma célula, de tratamento terapêutico, de determinação da presença de uma proteína, de diagnóstico da presença de um tumor e de distribuição de agente citotóxico.
ECSP14013195A (es) Catéter, en particular catéter permanente para el tratamiento de disfunciones y/o enfermedades de la vejiga y/o la próstata.
AU2014271207A1 (en) Targeted delivery of drugs to the myometrium
EP2999461A4 (en) Targeted delivery of drugs to the myometrium
HUE057565T2 (hu) Kettõs derivatizált kitozán nanorészecskék és módszerek azok elõállítására és felhasználására in vivo géntranszferhez
UY34154A (es) Dosificación y administración de anticuerpos anti-erbb3 en combinación con paclitaxel.
HK1206985A1 (en) Combination therapy of anti-mif antibodies and chemotherapeutics